Methodological considerations for measuring rates of brain atrophy

Methodological considerations for measuring rates of brain atrophy
复制标题

DOI:
10.1002/jmri.10325
复制
发表时间:
2003-07-01
影响因子:
4.4
通讯作者:
Jack, CR
Jack, CR
中科院分区:
医学2区
文献类型:
--
作者:
Gunter, JL;Shiung, MM;Jack, CR

文献摘要

被引文献

相似文献

目的:系统地比较连续磁共振成像 (MRI) 研究中测量脑萎缩率的两种技术。 材料和方法:以认知正常的老年受试者和阿尔茨海默病 (AD) 患者之间的脑萎缩率分离作为金标准,我们评估了 1) 计算体积变化的不同方法; 2) 图像预处理步骤的不同方法——强度归一化、使用的对准掩模和偏置场校正; 3)MRI采集硬件变化的影响; 4) 该方法对初始手动体积编辑变化的敏感性。对于前面的每项评估,都计算了全脑和脑室萎缩率的测量结果。结果:一般来说,通过脑室测量而不是全脑测量,临床组之间的分离更大。令人惊讶的是,使用偏置场校正或扫描对之间的主要硬件变化都不会影响组分离。结论:连续 MRI 的萎缩率测量结果可用作 AD 和其他痴呆性神经退行性疾病疾病进展的替代标志物。最终的方法具有出色的精度,并且准确地捕获了 AD 的预期生物学特征——如果将该技术用作疾病进展的生物标志物,这可以说是两个最重要的特征。
Purpose: To systematically compare two techniques for measuring brain atrophy rates from serial magnetic resonance imaging (MRI) studies.Materials and Methods: Using the separation in atrophy rate between cohorts of cognitively normal elderly subjects and patients with Alzheimer's disease (AD) as the gold standard, we evaluated 1) different methods of computing volume change; 2) different methods for steps in image preprocessing-intensity normalization, alignment mask used, and bias field correction; 3) the effect of MRI acquisition hardware changes; and 4) the sensitivity of the method to variations in initial manual volume editing. For each of the preceding evaluations, measurements of whole-brain and ventricular atrophy rates were calculated.Results: In general, greater separation between the clinical groups was seen with ventricular rather than whole-brain measures. Surprisingly, neither the use of bias field correction nor a major hardware change between the scan pairs affected group separation.Conclusion: Atrophy rate measurements from serial MRI are candidates for use as surrogate markers of disease progression in AD and other dementing neurodegenerative disorders. The final method has excellent precision and accurately captures the expected biology of AD-arguably the two most important features if this technique is to be used as a biomarker of disease progression.